Valuation: NetraMark Holdings Inc.

Market Cap 6.43Cr 4.64Cr 4Cr 3.76Cr 3.42Cr 443.56Cr 6.52Cr 44Cr 17Cr 222.22Cr 17Cr 17Cr 739.21Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.43Cr 4.64Cr 4Cr 3.76Cr 3.42Cr 443.56Cr 6.52Cr 44Cr 17Cr 222.22Cr 17Cr 17Cr 739.21Cr EV / Sales 2026 *
160x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
1 day+1.47%
1 week-4.17%
Current month-13.75%
1 month-13.75%
3 months-21.59%
6 months-32.35%
Current year-37.27%
1 week 0.64
Extreme 0.64
0.72
1 month 0.64
Extreme 0.64
0.85
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.98
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap.
13/04/26 Tax

Chairperson

4,34,178 0.4686%
19/02/26 Option

Executive/Senior Manager

1,16,250 0.1354%
19/02/26 Other

Executive/Senior Manager

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%-4.17%-58.43%+187.50% 4.64Cr
-3.07%-5.25%-7.27%+51.32% 3,67900Cr
-0.22%-0.83%-0.15%+1,128.06% 42TCr
-2.31%-4.29%+93.37%+176.42% 9.17TCr
+0.19%-2.15%-8.84%+47.42% 8.95TCr
-1.85%+0.24%-34.01%-2.70% 8.07TCr
-1.92%+3.96%-32.67%+202.23% 7.47TCr
-1.83%-4.46%+4.18%+75.45% 4.62TCr
-2.68%+3.85%-6.77%-14.90% 4.11TCr
-2.53%-7.40%+120.43%+294.61% 3.66TCr
Average -1.46%+1.23%+6.98%+214.54% 45.57TCr
Weighted average by Cap. -2.67%-0.32%-4.37%+155.70%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.76Cr 4L 27.44L 10.75L 1.38Cr 10.85L 10.62L 4.61Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
17/26/17 CA$0.6900 +1.47% 1,04,000
14/26/14 CA$0.6800 +3.03% 11,638
13/26/13 CA$0.6600 -1.49% 26,500
12/26/12 CA$0.6700 -4.29% 5,500
11/26/11 CA$0.7000 -2.78% 14,100

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock